Papers with the keyword ingenering (Page 2)

#21

JOURNAL ARTICLE

Challenging the gold standard: the limitations of molecular assays for detection of Mycobacterium tuberculosis heteroresistance.

Sarah N Danchuk, Ori E Solomon, Thomas Andreas Kohl, Viola Dreyer, Ivan Barilar, Christian Utpatel, Stefan Niemann, Dick van Soolingen, Richard Anthony, Jakko van Ingen, Joy S Michael, Marcel A Behr

OBJECTIVES: Heteroresistant infections are defined as infections in which a mixture of drug-resistant and drug-susceptible populations are present. In Mycobacterium tuberculosis ( M. tb ), heteroresistance poses a challenge in diagnosis and has been linked with poor treatment outcomes. We compared the analytical sensitivity of molecular methods, such as GeneXpert and whole genome sequencing (WGS) in detecting heteroresistance when compared with the 'gold standard' phenotypic assay: the agar proportion method (APM)...

38286614

January 29, 2024: Thorax

#22

JOURNAL ARTICLE

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

Billal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, Claire Mignard, Marie-Laure Golinski, Sébastien Calbo, Catherine Prost-Squarcioni, Bruno Labeille, Catherine Picard-Dahan, Guillaume Chaby, Marie-Aleth Richard, Emmanuelle Tancrede-Bohin, Sophie Duvert-Lehembre, Emmanuel Delaporte, Philippe Bernard, Frédéric Caux, Marina Alexandre, Philippe Musette, Saskia Ingen-Housz-Oro, Pierre Vabres, Gaëlle Quereux, Alain Dupuy, Sébastien Debarbieux, Martine Avenel-Audran, Michel D'Incan, Christophe Bédane, Nathalie Bénéton, Denis Jullien, Nicolas Dupin, Laurent Misery, Laurent Machet, Marie Beylot-Barry, Olivier Dereure, Bruno Sassolas, Jacques Benichou, Pascal Joly, Vivien Hébert

IMPORTANCE: The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available. OBJECTIVE: To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. DESIGN, SETTING, AND PARTICIPANTS: This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015...

38265821

January 24, 2024: JAMA Dermatology

#23

JOURNAL ARTICLE

Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model.

Sandra Salillas, Jelmer Raaijmakers, Rob E Aarnoutse, Elin M Svensson, Khalid Asouit, Erik van den Hombergh, Lindsey Te Brake, Ralf Stemkens, Heiman F L Wertheim, Wouter Hoefsloot, Jakko van Ingen

Mycobacterium avium complex pulmonary disease is treated with an azithromycin, ethambutol, and rifampicin regimen, with limited efficacy. The role of rifampicin is controversial due to inactivity, adverse effects, and drug interactions. Here, we evaluated the efficacy of clofazimine as a substitute for rifampicin in an intracellular hollow-fiber infection model. THP-1 cells, which are monocytes isolated from peripheral blood from an acute monocytic leukemia patient, were infected with M. avium ATCC 700898 and exposed to a regimen of azithromycin and ethambutol with either rifampicin or clofazimine...

38259101

January 23, 2024: Antimicrobial Agents and Chemotherapy

#24

JOURNAL ARTICLE

Mycobacterium avium complex pulmonary disease patients with limited treatment options.

Stefano Aliberti, Francesco Blasi, Pierre-Régis Burgel, Andrea Calcagno, Andreas Fløe, Dorothy Grogono, Apostolos Papavasileiou, Eva Polverino, Concepción Prados, Gernot Rohde, Helmut J F Salzer, Adrián Sánchez-Montalvá, Michal Shteinberg, Eva Van Braeckel, Jakko van Ingen, Nicolas Veziris, Dirk Wagner, Michael R Loebinger

How to identify MAC-PD patients with limited treatment options: an expert consensus https://bit.ly/3QwLQ8T.

38226066

January 2024: ERJ Open Research

#25

JOURNAL ARTICLE

New Neotropical and Nearctic species of water beetles in the genera Hydraena Kugelann and Ochthebius Leach, a key to North American genera and subgenera of the family, new distribution records, and a synopsis of ecology, behavior and morphology related to aquatic life (Coleoptera: Hydraenidae).

Philip D Perkins

Twenty-six new species of Hydraenidae are described, including new species from Belize (2), Mexico (16), Panama (3), St. Vincent (1), and the U.S.A. (4). High-resolution digital images of the habitus and male genitalia of holotypes are given. New distribution data are provided for 70 species, and new habitus and aedeagal images are given for members of the subgenus Spanglerina: H. (Spanglerina) brevis Sharp, H. (Spanglerina) frondsicola Perkins, and H. (Spanglerina) ingens Perkins. The following new species are described: Hydraena (Holcohydraena) chandleri, H...

38220730

November 7, 2023: Zootaxa

#26

JOURNAL ARTICLE

Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy.

Willem P J Cox, Nils Evander, Dorette S Van Ingen Schenau, Gawin R Stoll, Nadia Anderson, Lieke De Groot, Kari J T Grünewald, Rico Hagelaar, Miriam Butler, Roland P Kuiper, Laurens T Van der Meer, Frank N Van Leeuwen

In pediatric Acute Lymphoblastic Leukemia (ALL), mutations/deletions affecting the TP53 gene are rare at diagnosis. However, at relapse about 12% of the patients show TP53 aberrations, predicting a very poor outcome. Since p53-mediated apoptosis is an endpoint for many cytotoxic drugs, loss of p53 function frequently leads to therapy failure. In this study, we show that CRISPR/Cas9-induced loss of TP53 drives resistance to a large majority of drugs used to treat relapsed ALL, including novel agents such as inotuzumab ozogamicin...

38124624

December 21, 2023: Haematologica

#27

JOURNAL ARTICLE

CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion.

Theodoros Ioannis Papadimitriou, Prashant Singh, Arjan van Caam, Birgitte Walgreen, Mark A J Gorris, Elly L Vitters, Iris L van Ingen, Marije I Koenders, Ruben L Smeets, Madelon Vonk, Jolanda de Vries, Peter M van der Kraan, Ypke van Oosterhout, Martijn A Huijnen, Hans J P M Koenen, Rogier Thurlings

OBJECTIVES: Cytotoxic T cells and natural killer (NK) cells are central effector cells in cancer and infections. Their effector response is regulated by activating and inhibitory receptors. The regulation of these cells in systemic autoimmune diseases such as systemic sclerosis (SSc) is less defined. METHODS: We conducted ex vivo analysis of affected skin and blood samples from 4 SSc patient cohorts (a total of 165 SSc vs 80 healthy individuals) using single-cell transcriptomics, flow cytometry and multiplex immunofluorescence staining...

38123919

December 18, 2023: Annals of the Rheumatic Diseases

#28

JOURNAL ARTICLE

[Telephone follow-up as a part of the sepsis care process].

Johan Lindtsröm, Karolina Lager, Magnus Brink

In a pilot study of telephone follow-up as a part of the sepsis care process, no direct patient benefit could be demonstrated. A nurse with competency in infectious diseases called patients two to six weeks post-discharge after inpatient sepsis care to assess the need for further medical attention. Out of 51 eligible patients, only 21 telephone follow-ups could be realized. Supporting recommendations could be given in nine cases, but no direct medical advice was given. The follow-up was resource intensive; for each supporting recommendation, time used was calculated to 279 minutes...

38084634

December 12, 2023: Läkartidningen

#29

REVIEW

Advances in CO 2 activation by frustrated Lewis pairs: from stoichiometric to catalytic reactions.

Md Nasim Khan, Yara van Ingen, Tribani Boruah, Adam McLauchlan, Thomas Wirth, Rebecca L Melen

The rise of CO2 concentrations in the environment due to anthropogenic activities results in global warming and threatens the future of humanity and biodiversity. To address excessive CO2 emissions and its effects on climate change, efforts towards CO2 capture and conversion into value adduct products such as methane, methanol, acetic acid, and carbonates have grown. Frustrated Lewis pairs (FLPs) can activate small molecules, including CO2 and convert it into value added products. This review covers recent progress and mechanistic insights into intra- and inter-molecular FLPs comprised of varying Lewis acids and bases (from groups 13, 14, 15 of the periodic table as well as transition metals) that activate CO2 in stoichiometric and catalytic fashion towards reduced products...

38075657

December 6, 2023: Chemical Science

#30

JOURNAL ARTICLE

GC-MS Fingerprinting Combined with Chemical Pattern-Recognition Analysis Reveals Novel Chemical Markers of the Medicinal Seahorse.

Yuanyuan Jiang, Hongfei Wu, Paul Chi Lui Ho, Xuemei Tang, Hui Ao, Lu Chen, Jinjin Cai

Seahorse is a valuable marine-animal drug widely used in traditional Chinese medicine (TCM), and which was first documented in the "Ben Cao Jing Ji Zhu" during the Liang Dynasty. Hippocampus kelloggi (HK) is the most common seahorse species in the medicinal material market and is one of the genuine sources of medicinal seahorse documented in the Chinese pharmacopeia. It is mainly cultivated in the Shandong, Fujian, and Guangxi Provinces in China. However, pseudo-HK, represented by Hippocampus ingens (HI) due to its similar appearance and traits, is often found in the market, compromising the safety and efficacy of clinical use...

38067553

November 28, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry

#31

JOURNAL ARTICLE

Clofazimine is a safe and effective alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment - outcomes of a randomized trial.

Sanne M H Zweijpfenning, Rob Aarnoutse, Martin J Boeree, Cecile Magis-Escurra, Ralf Stemkens, Bram Geurts, Jakko van Ingen, Wouter Hoefsloot

BACKGROUND: Retrospective studies have suggested clofazimine as an alternative for rifampicin in MAC-PD treatment. RESEARCH QUESTION: Is a treatment regimen consisting of clofazimine-ethambutol-macrolide non inferior to the standard treatment regimen (rifampicin-ethambutol-macrolide) in the treatment of M.avium complex pulmonary disease? STUDY DESIGN AND METHODS: In this single centre non-blinded clinical trial, we randomly assigned adult patients with MAC-PD in a 1:1 ratio to receive rifampicin or clofazimine as adjuncts to an ethambutol-macrolide backbone...

38040054

November 29, 2023: Chest

#32

Acute allergic contact dermatitis caused by sulphites in a cosmetic and a pharmaceutical cream.

Valérie Beaulieu, Ilaria Matei, Nancy Hajjar, Saskia Ingen-Housz-Oro, Haudrey Assier

No abstract text is available yet for this article.

38037715

December 1, 2023: Contact Dermatitis

#33

JOURNAL ARTICLE

Successful addition of topical antibiotic treatment after surgery in treatment-refractory nontuberculous mycobacterial skin and soft tissue infections.

Ralf Stemkens, Maarten Cobussen, Erik de Laat, Wouter Hoefsloot, Reinout van Crevel, Rob E Aarnoutse, Jakko van Ingen

Treatment of skin and soft tissue infections with nontuberculous mycobacteria sometimes fails despite repeated debridements and long-term systemic antibiotic therapy. These treatment-refractory infections can cause significant morbidity and pose a treatment challenge. Following surgery, we treated three patients with negative pressure wound therapy with the instillation and dwell time of topical antibiotics, in addition to systemic antibiotic treatment. Treatment was successful and well tolerated, except for some local irritation...

38014946

December 14, 2023: Antimicrobial Agents and Chemotherapy

#34

DRESS to loxapine and avoidable recurrence with clozapine.

Ilaria Matei, Amandine Weill, Kamar Bel Hareth, Saskia Ingen-Housz-Oro, Haudrey Assier

No abstract text is available yet for this article.

37990777

November 21, 2023: Contact Dermatitis

#35

JOURNAL ARTICLE

Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus.

Marie-Charlotte Brüggen, Sarah Walsh, M Milad Ameri, Natalie Anasiewicz, Emanual Maverakis, Lars E French, Saskia Ingen-Housz-Oro, Richiiro Abe, Michael Ardern-Jones, Haudrey Assier, Annick Barbaud, Benoit Bensaid, William Bernal, Claire Bernier, Alain Brassard, Eva Brezinová, Rosario Cabañas, Adela Cardones, Chia-Yu Chu, Ser-Ling Chua, Vincent Descamps, Biagio Didona, Sherrie Jill Divito, Roni Dodiuk-Gad, Scott Elman, Krisztian Gaspar, Charlotte G Mortz, Natsumi Hama, Haur Yueh Lee, Barbara Horváth, Lukas Jörg, Benjamin H Kaffenberger, Vesta Kucinskiene, Bénédicte Lebrun-Vignes, Rannakoe J Lehloenya, Damian Meyersburg, Robert Micheletti, Brigitte Milpied, Fumi Miyagawa, Arash Mostaghimi, Mirjam Nägeli, Luigi Naldi, Eva Oppel, Elizabeth J Phillips, Tasneem Pirani, Annamari Ranki, Tarja Mälkönen, Misha Rosenbach, Carmen Salavastru, Delphine Staumont-Salle, Heidi Sandberg, Jane Setterfield, Kanade Shinkai, Tetsuo Shiohara, Angele Soria, Danielle Tartar, George-Sorin Tiplica, Stephan Traidl, Artem Vorobyev, Camilla von Wachter, Scott Worswick, Yung-Tsu Cho

IMPORTANCE: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment. OBJECTIVE: To reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS. DESIGN, SETTING, AND PARTICIPANTS: The Delphi method was used to assess 100 statements related to baseline workup, evaluation of severity, acute phase, and postacute management of DRESS...

37966824

January 1, 2024: JAMA Dermatology

#36

JOURNAL ARTICLE

[Not Available].

Axel Nordenskjöld, Pouya Movahed

No abstract text is available yet for this article.

37966105

November 15, 2023: Läkartidningen

#37

JOURNAL ARTICLE

No gold standard for calculating excess mortality.

Ann Kristin Skrindo Knudsen, Ingeborg Forthun, Christian Madsen

No abstract text is available yet for this article.

37938010

November 7, 2023: Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række

#38

JOURNAL ARTICLE

[Local treatments for bullous pemphigoid].

Christelle Le Roux-Villet, Ingrid Hurtel, Céline Lastiri, Saskia Ingen-Housz-Oro, Sophie Duvert-Lehembre

Bullous pemphigoid affects people who are usually very frail, because they are very old and frequently have neurological co-morbidities. Over the past twenty years, therapeutic management has improved thanks to the application of highly potent corticosteroid-based creams, following a well-established regimen, for several months. Well-conducted nursing care is therefore essential not only to cover wounds, but also to treat the disease. Dedicated nursing time is also an opportunity to provide support to patients, who are often very uncomfortable...

37931999

November 2023: Soins; la Revue de Référence Infirmière

#39

JOURNAL ARTICLE

Reactivity of a series of triaryl borates, B(OAr x ) 3 , in hydroboration catalysis.

Tomasz Sokolnicki, Mashael M Alharbi, Yara van Ingen, Shahnaz Rahim, Milan Pramanik, Alberto Roldan, Jędrzej Walkowiak, Rebecca L Melen

In this paper, we compare the reactivity of a series of triaryl borates B(OArx )3 as catalysts for the hydroboration of alkenes and alkynes. It was observed that commercially available B(OPh)3 performed the poorest, whereas catalysts with o -F atoms appeared to perform much better.

37901910

October 30, 2023: Dalton Transactions: An International Journal of Inorganic Chemistry

#40

JOURNAL ARTICLE

The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease.

Jodie A Schildkraut, Jelmer Raaijmakers, Rob Aarnoutse, Wouter Hoefsloot, Heiman F L Wertheim, Jakko van Ingen

Rifampicin is recommended for the treatment of Mycobacterium avium complex pulmonary disease alongside azithromycin and ethambutol. We evaluated the azithromycin-ethambutol backbone with and without rifampicin in an intracellular hollow fiber model and performed RNA sequencing to study the differences in adaptation. In an in vitro hollow fiber experiment, we simulated epithelial lining fluid pharmacokinetic profiles of the recommended 3-drug (rifampicin, ethambutol, and azithromycin) or a 2-drug (ethambutol and azithromycin) treatment...

37877693

November 15, 2023: Antimicrobial Agents and Chemotherapy

Use the keywords feature with a free QxMD account.

ingenering

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips